These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11028833)

  • 1. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain.
    Haus U; Varga B; Stratz T; Späth M; Müller W
    Scand J Rheumatol Suppl; 2000; 113():55-8. PubMed ID: 11028833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
    Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
    Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the intravenous administration of tropisetron in fibromyalgia patients.
    Müller W; Stratz T
    Scand J Rheumatol Suppl; 2000; 113():59-62. PubMed ID: 11028834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
    Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
    Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibromyalgia treatment with intravenous tropisetron administration.
    Stratz T; Färber L; Varga B; Baumgartner C; Haus U; Müller W
    Drugs Exp Clin Res; 2001; 27(3):113-8. PubMed ID: 11447769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia].
    Stratz T; Varga B; Müller W
    Z Rheumatol; 2003 Feb; 62(1):42-5. PubMed ID: 12624803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
    Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
    Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose.
    Samborski W; Stratz T; Lacki JK; Klama K; Mennet P; Müller W
    Mater Med Pol; 1996; 28(1):17-9. PubMed ID: 9088121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience.
    Kohnen R; Färber L; Späth M
    Scand J Rheumatol Suppl; 2004; 119():67-71. PubMed ID: 15515419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].
    Stratz T; Müller W
    Fortschr Med Orig; 2002; 120(1):17-20. PubMed ID: 14518353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study.
    Papadopoulos IA; Georgiou PE; Katsimbri PP; Drosos AA
    Clin Rheumatol; 2000; 19(1):6-8. PubMed ID: 10752491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia?
    Stratz T; Müller W
    Scand J Rheumatol Suppl; 2000; 113():63-5. PubMed ID: 11028835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of fibromyalgia with tropisetron--dose and efficacy correlations.
    Späth M; Stratz T; Färber L; Haus U; Pongratz D
    Scand J Rheumatol Suppl; 2004; 119():63-6. PubMed ID: 15515418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors].
    Stratz T; Schochat T; Hrycaj P; Lacki J; Mennet P; Färber L; Schweiger C; Müller W
    Z Rheumatol; 1994; 53(6):335-8. PubMed ID: 7871905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice.
    Tolk J; Kohnen R; Müller W
    Scand J Rheumatol Suppl; 2004; 119():72-5. PubMed ID: 15515420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia.
    Höcherl K; Färber L; Ladenburger S; Vosshage D; Stratz T; Müller W; Grobecker H
    Scand J Rheumatol Suppl; 2000; 113():46-8. PubMed ID: 11028831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia?
    Stratz T; Kees F; Müller W
    Drugs Exp Clin Res; 2003; 29(2):91-4. PubMed ID: 12951840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome.
    Seidel MF; Weinreich GF; Stratz T; Müller W
    Rheumatol Int; 2007 Sep; 27(11):1025-30. PubMed ID: 17634903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder.
    Lecrubier Y; Puech AJ; Azcona A; Bailey PE; Lataste X
    Psychopharmacology (Berl); 1993; 112(1):129-33. PubMed ID: 7871001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia.
    Arnold LM; Leon T; Whalen E; Barrett J
    Psychosomatics; 2010; 51(6):489-97. PubMed ID: 21051680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.